Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,801–1,900 of 2,656
Patoulias, D., & Popovic, D. S. (2023) · International Urology and Nephrology · doi:10.1007/s11255-023-03618-w · Cited by 1
Care of the Patient With Abnormal Kidney Test Results
Tuot, D. S., & Powe, N. R. (2023) · Annals of Internal Medicine · doi:10.7326/aitc202305160
Hintze, S. C., & Terkamp, C. (2023) · Diabetes aktuell · doi:10.1055/a-2068-3412
“[15] Herrington W, Staplin N, Wanner C et al.”
BackgroundInfluentialFusco, S. A. D., Spinelli, A., Aquilani, S., Borrelli, N., Iannopollo, G., Gulizia, M. M., Gabrielli, D., Oliva, F. G., & Colivicchi, F. (2023) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suad107
Bancks, M. P. (2023) · Diabetes Care · doi:10.2337/dci23-0023
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · doi:10.2337/figshare.22186279.v1
Dapagliflozin and Correction of Anemia in Patients with CKD
Singh, A. K. (2023) · NEJM Evidence · doi:10.1056/evide2300095
A vese védelmében és azon is túl. A renoprotekció új lehetőségei
Balogh, D. B., Fekete, A., & Reusz, G. (2023) · Hypertonia és Nephrologia · doi:10.33668/hn.27.013
Dapagliflozin vermindert das Risiko für Krankenhausaufenthalte von Typ-2-Diabetes-Patienten
Schamarek, I. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01060-1
Corigliano, G. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.1.8
New therapeutic options for IgA nephropathy: Balancing risks and benefits
Pontremoli, R., & Ghinatti, M. C. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.06.016
Chapman, D., Judge, P. K., Arnold, T., Staplin, N., Clark, S., Haynes, R., Moffat, S., Herrington, W. G., & Hill, M. (2023) · Kidney International · doi:10.1016/j.kint.2023.03.032
SGLT2-Hemmer als renale Basistherapie? KDIGO-Leitlinien Diabetes 2022
Wanner, C. (2023) · CardioVasc · doi:10.1007/s15027-023-3013-x
Roser, P., & Aberle, J. (2023) · CardioVasc · doi:10.1007/s15027-023-3012-y
Flekač, M. (2023) · Vnitřní lékařství · doi:10.36290/vnl.2023.051
Evidencias de los iSGLT2 en el tratamiento de la enfermedad renal crónica
Montero, A. C. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102019 · Cited by 2
Moraga, M. J. C., Turégano-Yedro, M., & Pallarés‐Carratalá, V. (2023) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2023.102020 · Cited by 1
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
Schirmer, S. H. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4512-7
Die neuen Wunderdrogen - eine Einordnung aus nephrologischer Sicht
Weinmann‐Menke, J., & Kraus, D. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4511-8
González, F. (2023) · ARS MEDICA Revista de Ciencias Médicas · doi:10.11565/arsmed.v48i2.1990
Zhou, L., Zhang, Y., Huang, Z., Xu, T., & Li, Y. (2023) · Research Square · doi:10.21203/rs.3.rs-3179827/v1
Strubbe, M., Caerels, S., David, K., Naesens, M., Vanassche, T., Mertens, A. C., & Mathieu, C. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.79.23.015
Neue orale Antidiabetika in der Therapie des geriatrischen Patienten
Bahrmann, A. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-1780-4175
Advice and challenges in the pharmacotherapeutic management of diabetic kidney disease in adults
Plattner, C., Pirklbauer, M., & Mayer, G. J. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2244420
“Extrapolation of effects on eGFR suggested that SGLT2 inhibitor use could result in several additional years without renal replacement therapy in comparison to controls [29,30].”
BackgroundResultInfluentialKardiorenale Risikoreduktion bei Diabetes
Berger, M., & Schütt, K. S. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01090-9
The decline in kidney function after heart transplantation and its impact on survival
Chaemchoi, T., Ittiwattanakul, W., Ritteeverakul, P., Intrarakamhang, A., Thammanatsakul, K., Sinphurmsukskul, S., Siwamogsatham, S., Puwanant, S., & Ariyachaipanich, A. (2023) · Clinical Transplantation · doi:10.1111/ctr.15112
Herzinsuffizienz: Das sind die neuen Leitlinien-Empfehlungen
Overbeck, P. (2023) · MMW - Fortschritte der Medizin · doi:10.1007/s15006-023-2974-0
Medikamentöse Herzinsuffizienztherapie bei CKD
Schütt, K. S., & Marx, N. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00685-z
Sun, Y., Zhou, Y., Xu, D., Liu, M., & Yu, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3268087/v1
SGLT2 inhibitors: here we go again?
Will, E. J. (2023) · BMJ · doi:10.1136/bmj.p2172
Gallwitz, B., Kellerer, M., Müller‐Wieland, D., Wanner, C., & Ziemssen, F. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2149-3554
“[63] The EMPA-KIDNEY Collaborative Group; Herrington.”
BackgroundMilder, T. Y., Milder, D. A., Greenfield, J. R., et al. (2023) · Drug Safety · doi:10.1007/s40264-023-01358-5
Neue orale Antidiabetika in der Therapie des geriatrischen Patienten
Bahrmann, A. (2023) · Geriatrie up2date · doi:10.1055/a-2158-3158
Shubrook, J. H., Neumiller, J. J., Alicic, R. Z., Manley, T., & Tuttle, K. R. (2023) · Diabetology · doi:10.3390/diabetology4040039
Highlights from the Diabetes UK Professional Conference 2023
Bishop, K. (2023) · Prescriber · doi:10.1002/psb.2096
Mankovsky, B., Saienko, Y. A., Bilchenko, O. V., Dudar, І., Zaichenko, H. V., Ivanov, D., Komisarenko, Y., Sokolova, L., Urbanovych, A., Yuzvenko, T., et al. (2023) · Diabetes Obesity Metabolic Syndrome · doi:10.57105/2415-7252-2023-5-04
Journal Scan: Updates from Important Trials in Cardiology of 2022 (4th quarter of 2022)
Cader, F. A., & Khan, S. R. (2023) · Ibrahim Cardiac Medical Journal · doi:10.3329/icmj.v12i2.69865
Geschlechtsspezifische Unterschiede in der Progression von diabetischen Nierenerkrankungen
Gerdes, C., Wolf, G., & Loeffler, I. (2023) · Die Nephrologie · doi:10.1007/s11560-023-00694-y
The times they are K+-changin’: bringing the potassium curriculum out of the 20th century
Hoenig, M. P., Lecker, S. H., & William, J. H. (2023) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000958
Using PET imaging as tool to unravel drug response variability in type 2 diabetes
van der Hoek, S. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.845383131
Tratamiento y seguimiento de personas con diabetes mellitus y enfermedad renal crónica
Bravo, J. J. M. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art7
Tratamiento actual de la insuficiencia cardíaca con fracción de eyección preservada
Quintero, M. A. R. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.icfracciondeeyeccion.art5 · Cited by 1
Ghnaimat, M. A., Al-Samen, M. A. A., Hijleh, M. O. A., Jarrah, N. S., Al-Momani, M., Barghouthi, H., Khawaldeh, A., Khoury, T., Said, R. A., & Matalka, M. S. (2023) · Journal of Family Medicine and Health Care · doi:10.11648/j.jfmhc.20230903.13
Insuficiencia cardíaca. Estrategias diagnósticas y terapéuticas
Amores, M., & Zamorano, J. L. (2023) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2023.12.004
Seoudy, H., Voran, J. C., & Frank, D. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.3116
Alsheikh, A., Al-Jedai, A. H., Almudaiheem, H., Alaidarous, S. B., Alshehri, A. A., Elbadawi, H., Alghamdi, S., Aljehani, F., Alobaidi, S. A., Altuwaijri, T. A., et al. (2023) · International Journal of Clinical Medicine · doi:10.4236/ijcm.2023.1412045
Kuan, Y. L., & Abdul Halim, A. G. (2023) · Medicine & health · doi:10.17576/mh.2023.1802.05
Antihypertensive Effects of SGLT2-Inhibitors: Considerations for Clinical Practice
Porto, A. D., Bulfone, L., & Sechi, L. A. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611274645231208102130
Perioperative Ketoacidosis with SGLT-2 Inhibitors: More Lessons to Learn
(2023) · Journal of Research & Innovation in Anesthesia · doi:10.5005/jp-journals-10049-2031
Particularités des complications microangiopathiques du diabète chez le sujet âgé
Buysschaert, M., Boureau, A., Dhane, Y., & Bauduceau, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(23)00297-3
Shtoyko, A. N., Murphy, M. B., Harris, J. L., Toomey, C., & Phillips, E. M. (2024) · Diabetes Spectrum · doi:10.2337/ds22-0095
Böhm, M., Perings, C., Bauersachs, J. K., Edelmann, F., Färber, G., Heidecker, B., Paul, M., & Pauschinger, M. (2024) · Die Kardiologie · doi:10.1007/s12181-023-00655-8
Шамхалова, М. Ш., Sukhareva, O. Y., & Yevloyeva, M. I. (2023) · Diabetes Mellitus · doi:10.14341/dm13107 · Cited by 1
Freitas, J. C., Francisco, J. T., Trigo, M., Carvalho, R., Vilela, S., Silvano, J., Ribeiro, C., Malheiro, J., Pedroso, S., Almeida, M., et al. (2024) · Brazilian Journal of Transplantation · doi:10.53855/bjt.v27i1.546_eng
Kremneva, L. V., Arutyunyan, L. A., Gapon, L. I., Suplotov, S. N., & Шалаев, С. В. (2023) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2023-2985
Improvements in Kidney Outcomes Over the Years: Reason for Optimism but a Challenge for Trialists
Zhu, D., Judge, P. K., & Haynes, R. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.12.008
Sun, W. J., & Yan, B. P. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003544
Aktuelle Therapie der Herzinsuffizienz mit mäßiggradig reduzierter und erhaltener Pumpfunktion
Störk, S., & Morbach, C. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2047-5013
“Zudem kann durch SGLT2-Hemmer der Einsatz an Diure-tika vermindert und ein additiver nephroprotektiver Ef-fekt erwartet werden [16, 17].”
BackgroundMartínez, M. G., Vidal, M. J., Valverde, A. R. D. A., et al. (2024) · Revista Clínica Española · doi:10.1016/j.rce.2023.08.005
Peran SGLT2i terhadap Risiko Kardiorenal Pasien dengan atau Tanpa Diabetes Melitus Tipe 2
Allen (2024) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v51i2.873
Floyd, L., & Delanaye, P. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae031
“…participants with CVD, type 2 diabetes mellitus ( T2DM) and raised urine ACR measurements was significantly higher in RCTs such as FIDELIO-DKD [8 ], DAPA-CKD [7 ], and EMPA-KIDNEY [9 ] compared to the general population included in the THOMAS study and other population-based screening studies [4 ].”
ResultCarvalho, M., & Heilberg, I. P. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0146pt
“Em 2019 e 2021, o DAPA-CKD e o CREDENCE (que envolveram apenas diabéticos) e em 2022 o EMPA-KIDNEY, demonstraram que os iSGLT2 melhoram os desfechos renais e retardam a progressão da DRC, independentemente da presença de DM e em todas as categorias de risco do KDIGO 7,8 .”
BackgroundDiuretika bei akuter und chronischer Nierenkrankheit
Bohnert, B. N. (2024) · Nephrologie aktuell · doi:10.1055/a-2187-3045
Mishriky, B. M., Cummings, D. M., Fu, Y., Halladay, J. R., Jones, S., Boan, A. D., Jones, S. B., Patil, S. P., Powell, J. R., Adams, A. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15499
Akyıldız, İ., & Baysan, O. (2023) · Heart Vessels and Transplantation · doi:10.24969/hvt.2023.443
Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research
夏, 小. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.142429
Enhancing patient outcomes: 2023 focused clinical update on heart failure
Lehane, M., Docherty, A., Hyland, B., Simpson, M., & Macklin, L. (2024) · British Journal of Cardiac Nursing · doi:10.12968/bjca.2023.0103
Factores de progresión en pacientes con ERC-3 KDOQI (estudio PROGRESER)
Martínez‐Castelao, A., Górriz, J. L., D’Marco, L., Garrigós, E., Fernández‐Fresnedo, G., Espinel, E., Cigarrán, S., Coloma, J. A., Pérez-Monteoliva, N. R. R., de la Rosa, R. J. E., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.02.009 · Cited by 3
Low-Protein Diets and Its Synergistic Role in the SGLT2 Inhibitor Era
Patel, J., Kalantar‐Zadeh, K., & Joshi, S. (2023) · Advances in Kidney Disease and Health · doi:10.1053/j.akdh.2023.12.005
Roddick, A., Whitehouse, A., Petrini, M., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae057
Wang, C.-A., Lin, L.-C., Chen, J., Wang, W., & Wu, V. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4751279
SGLT-2-Inhibitoren: So profitieren Patienten in der Praxis
(2024) · Info Diabetologie · doi:10.1007/s15034-024-4915-0
Madagam, S. (2024) · Urinary and Renal Research · doi:10.54517/urr.v5i1.2402
Renoprotective interventions efficacy in the late stages of CKD
Sadovskaya, D. S. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004361
Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
Tarun, T., Davis, O. M., Ghanta, S. N., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.03.027
Prevention and management of chronic kidney disease in diabetes
Barlovič, D. P., & Groop, P. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-88426-6.00004-x
Pharmacological Management of CKD
Corr, M. (2024) · Principles of specialty nursing · doi:10.1007/978-3-031-30320-3_4
Gollmer, J., Zirlik, A., & Bugger, H. (2024) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2226-0683
Gîrdan, L., Gavris, C. M., & Nedelcu, L. D. (2024) · Jurnal Medical Brasovean · doi:10.31926/jmb.2023.1.4 · Cited by 1
Sodium-Glucose Cotransporter 2 Inhibitors for Chronic Kidney Disease: A Comprehensive Review
Song, S. H., & Bae, E. H. (2024) · Korean Journal of Medicine · doi:10.3904/kjm.2024.99.2.61
Chen, H., Li, D.-Y., Meng, R., Yang, Y., & Yu, T.-H. (2024) · Research Square · doi:10.21203/rs.3.rs-4131335/v1
Metabolic effects of glyphlozines
Krčma, M. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.019
Santos, A. M. S., de Carvalho, C. J., Lopes, A. D. C. P., Ruas, S. K. J., Paseto, E. D., Arruda, L. V. M., & Colombari, J. P. C. (2024) · doi:10.22533/at.ed.46824120412
SÍFILIS CONGÊNITA: ASPECTOS EPIDEMIOLÓGICOS EM MARÍLIA-SP
Azevedo, G. B., & Rubira, C. J. (2024) · doi:10.22533/at.ed.46824120416
O NEUROPSICOPEDAGOGO NA EQUIPE MULTIDISCIPLINAR DE TRATAMENTO DA DEPENDÊNCIA QUÍMICA
Girolamo, F. D. F. F. P. P. D. (2024) · doi:10.22533/at.ed.46824120413
VESICULA BILIAR DUPLICADA: RELATO DE CASO
Sperotto, E. A., Urzagaste, C. H. V., Urzagaste, M. V., & Urzagaste, R. V. (2024) · doi:10.22533/at.ed.46824120418
Guerra, D. K. H., de Oliveira, V. G., da Silveira, I. C. B., Moreira, E. V. S., Filho, V. T. A. M., Neto, J. A., Braga, V., Portela, J. E. G., de Oliveira, A. A., de Sousa, M. B. M., et al. (2024) · doi:10.22533/at.ed.4682412041
FATORES QUE INFLUENCIAM O INICIO TARDIO DO PRÉ-NATAL
da Silva, A. V., de Carvalho, A. K. P., Neri, D. T., Pena, L. D., Joubert, P. P., Braga, V. D. S., & Gomes, V. R. (2024) · doi:10.22533/at.ed.4682412045
MENINGITES BACTERIANAS ASPECTOS INTRODUTORIOS E PROFILÁTICOS
Netto, F. D. F., Gehring, G. M., Mansani, F. P., Cordeiro, T. M. G., Benitez, J. G., Mayer, R., Machado, L. G. P., Gomes, R. Z., Derbli, E. S., Jecohti, V. M., et al. (2024) · doi:10.22533/at.ed.4682412049
Oliveira, A. C. B. C. D. C., Granja, C. E. L., de lírio, L. R., Bellegarde, K., Torres, L. C., Bispo, J. V., Cunha, F. A. G., Groke, M. J. Q., Cadamuro, M. D. P. D. R., Gomes, F. B. T., et al. (2024) · doi:10.22533/at.ed.4682412047
ESTIGMA E ACEITAÇÃO: EXPLORANDO AS DIMENSÕES SOCIAIS DO PÉ TORTO CONGÊNITO NA INFÂNCIA
Oliva, A. D. O., Rosa, P. C. G., Furlan, J. B., Bueno, N. S., Alssuffi, J. E. A., Figueiredo, E. V., de Castro, G. G., Becegatto, T. F., Silva, A. L. B., Cavalcante, F. R. P., et al. (2024) · doi:10.22533/at.ed.4682412044
RETATRUTIDA NO TRATAMENTO DA OBESIDADE: AVALIAÇÃO DA EFICÁCIA E EVIDÊNCIAS CLÍNICAS
Guerra, D. K. H., Amâncio, S. A., Figueiredo, A. D. S., Coutinho, C. C. C., Moreira, E. V. S., Aguiar, G. B. C., Coelho, J. M., Barbosa, L. G., de Melo, M. C. S., Guimarães, R. V., et al. (2024) · doi:10.22533/at.ed.46824120415
Jornada médica: desafios e triunfos na prática da medicina 5
Neto, B. R. D. S. (2024) · doi:10.22533/at.ed.468241204
MORBIDADE HOSPITALAR DO SUS POR AFECÇÕES PROSTÁTICAS NO PERÍODO DE 2020 A 2021 EM FORTALEZA, CE
Ponte, R. M. A., de Oliveira, A. A., Carneiro, A. G. A., Coutinho, C. C. C., da Silva, C. W. F., Neto, F. H. D. S., Coelho, J. M., Neto, J. A., Feitosa, L. A. M., Costa, M. P., et al. (2024) · doi:10.22533/at.ed.46824120410
MUDANÇA DE AUTODETERMINAÇÃO DE GÊNERO EM PACIENTE EM EPISÓDIO PSICÓTICO MANIFORME: RELATO DE CASO
Gonçalves, L. F. C., Casquer, M. S., Welter, P. M. G., & Freire, S. D. (2024) · doi:10.22533/at.ed.46824120411
Ponte, R. M. A., de Oliveira, A. A., de Sousa, A. F., Fitaroni, A. C. V. A. M., Gomes, D. R. P., Teixeira, I. C., Caetano, J. V. D. M., Coelho, J. M., Fales, L. T. D. C. C., Silva, P. V. T. S., et al. (2024) · doi:10.22533/at.ed.4682412042
ESPIRITUALIDADE NOS CUIDADOS PALIATIVOS EM PACIENTES PEDIÁTRICOS: UMA REVISÃO DE LITERATURA
Amâncio, L. D. M. F., Moreira, L. D. C., de Souza, L. K. C., Ferreira, K. C., Novaes, B. H. G. D. S., Maciel, G. R., de Sousa, I. S., Miranda, Y. R. V., Figueiredo, L. P. L. R., Silva, C. M. D. M., et al. (2024) · doi:10.22533/at.ed.4682412043
do Amaral, M. V. F., Urzagaste, C. H. V., Guerra, E. E., Urzagaste, R. V., & Urzagaste, M. V. (2024) · doi:10.22533/at.ed.4682412046
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.